EA201991531A1 - Способы лечения композициями линаклотида с отсроченным высвобождением - Google Patents

Способы лечения композициями линаклотида с отсроченным высвобождением

Info

Publication number
EA201991531A1
EA201991531A1 EA201991531A EA201991531A EA201991531A1 EA 201991531 A1 EA201991531 A1 EA 201991531A1 EA 201991531 A EA201991531 A EA 201991531A EA 201991531 A EA201991531 A EA 201991531A EA 201991531 A1 EA201991531 A1 EA 201991531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
treatment
delayed delivery
gastrointestinal tract
linaclotide
Prior art date
Application number
EA201991531A
Other languages
English (en)
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991531A1 publication Critical patent/EA201991531A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201991531A 2016-12-21 2017-12-21 Способы лечения композициями линаклотида с отсроченным высвобождением EA201991531A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437566P 2016-12-21 2016-12-21
PCT/US2017/067814 WO2018119191A1 (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Publications (1)

Publication Number Publication Date
EA201991531A1 true EA201991531A1 (ru) 2019-11-29

Family

ID=61022424

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991531A EA201991531A1 (ru) 2016-12-21 2017-12-21 Способы лечения композициями линаклотида с отсроченным высвобождением

Country Status (10)

Country Link
EP (1) EP3558337A1 (enrdf_load_stackoverflow)
JP (2) JP2020512292A (enrdf_load_stackoverflow)
CN (1) CN110475564A (enrdf_load_stackoverflow)
AU (1) AU2017379082A1 (enrdf_load_stackoverflow)
BR (1) BR112019012689A2 (enrdf_load_stackoverflow)
CA (1) CA3048195A1 (enrdf_load_stackoverflow)
EA (1) EA201991531A1 (enrdf_load_stackoverflow)
MA (1) MA47112A (enrdf_load_stackoverflow)
MX (2) MX2019007574A (enrdf_load_stackoverflow)
WO (1) WO2018119191A1 (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140528A1 (en) * 2019-06-10 2020-12-17 Wilmin Bartolini Treatment of abdominal pain associated with diarrhea-predominant irritable bowel syndrome
KR20240111797A (ko) * 2021-11-29 2024-07-17 아이언우드 파마슈티컬스, 인코포레이티드 내장 통증의 치료를 위한 제약 조성물
WO2023196821A2 (en) * 2022-04-04 2023-10-12 Thomas Jefferson University Targeting neuropod cell gucy2c to control visceral pain and appetite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PL2328601T3 (pl) 2008-08-15 2020-07-13 Ironwood Pharmaceuticals, Inc. Formulacje zawierające linaklotyd do podawania doustnego
EP2464373A1 (en) * 2009-08-13 2012-06-20 Ironwood Pharmaceuticals, Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
PL2536742T3 (pl) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Leczenie zaburzeń żołądkowo-jelitowych
ES2763404T3 (es) * 2010-08-11 2020-05-28 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
US9708371B2 (en) * 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
BR112015016917B1 (pt) * 2013-01-15 2022-08-30 Ironwood Pharmaceuticals, Inc Forma de dosagem oral de retenção gástrica, e, uso de um sequestrante de ácido biliar
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide

Also Published As

Publication number Publication date
CA3048195A1 (en) 2018-06-28
MX2019007574A (es) 2019-09-04
BR112019012689A2 (pt) 2019-11-19
JP2022093472A (ja) 2022-06-23
WO2018119191A9 (en) 2018-10-18
EP3558337A1 (en) 2019-10-30
MA47112A (fr) 2019-10-30
JP2020512292A (ja) 2020-04-23
MX2023008839A (es) 2023-08-14
WO2018119191A1 (en) 2018-06-28
CN110475564A (zh) 2019-11-19
AU2017379082A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
EA202090683A2 (ru) Способы и композиции для лечения рака
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591925A1 (ru) Терапевтические композиции и их применение
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX382175B (es) Composiciones de profármaco de monometilfumarato
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
MX2015016492A (es) Peptidos de y conotoxina, composicion farmaceutica y usos de los mismos.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
MX2016008968A (es) Compuestos organicos.